Tessera Therapeutics
PrivateLast Round
Grant
Mar 23, 2026
Total Funding Raised
$621.3M
Momentum Score
25 /100
Company Overview
Tessera (Biotechnology) is a genetic engineering company that develops gene writing technology to facilitate permanent modifications to the human genome for therapeutic purposes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tessera Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Tessera Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 23, 2026 | ||||
| Strategic | Dec 18, 2024 | ||||
| Series C | Apr 19, 2022 | ||||
| Series B | Jan 12, 2021 | ||||
| Series A | Jul 7, 2020 |
Key People
Founding team and executive leadership
Tessera Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SoftBank Investment Advisers | Series C, Series B |
| Altitude Life Science Ventures | Series C, Series B |
| Longevity Vision Fund | Series C |
| ARTIS Ventures | Series C |
| SoftBank Group | Series C, Series B |
| T. Rowe Price | Series C |
| Bill & Melinda Gates Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 23, 2026
$41.3M raised in grant funding.
- Mar 23, 2026
Developing curative in vivo genetic treatment for sickle cell disease.
Tessera Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Tessera Therapeutics's valuation, stock price, and market status.
